Compare · Health Care
Eli Lilly vs. Merck: how they make money
The same facts for both companies, in the same order, from each company's own page and filings. It is not a ranking.
How they differ
In FY2025, Eli Lilly and Merck reported revenue within 5% of each other: $65.2B and $65.0B.
Eli Lilly's largest segment is Cardiometabolic health, 74.0% of revenue in FY2025; Merck's largest segment is Pharmaceutical, 89.4% of revenue in FY2025.
United States brought in 66.7% of Eli Lilly's revenue in FY2025; United States brought in 56.2% of Merck's revenue in FY2025.
Eli Lilly's largest payer group is Customers in the US, 66.7% of revenue (FY2025); Merck's largest payer group is Customers in the US, 56.2% of revenue (FY2025).
Neither page lists the other among its competitors.
Each company in 5 points
Eli Lilly
1 · What it sells
Eli Lilly sells medicines in about 90 countries, and two brands, Mounjaro and Zepbound, were 56% of its $65.2 billion of FY2025 revenue.
Sources and detail on the Eli Lilly page2 · Who pays it
Lilly does not report revenue by final payer and three US wholesalers each bought 16 to 24 percent; by location, in FY2025 the US paid 66.7% of revenue, Europe 17.7%, Japan 3.3%, China 3.0% and the rest of the world 9.3%.
Sources and detail on the Eli Lilly page3 · What it keeps from $100
Of every $100 of FY2025 revenue, Lilly kept $31.7 as net income, after $0.9 of net non-operating costs and $4.5 of acquired research, a deal cost that reached $17.1 in Q3 FY2026; operating income, stated in its earnings release, was $40.4.
Sources and detail on the Eli Lilly page4 · Where the operating profit comes from
Lilly reports one segment and no profit by product, so its $26.3 billion of FY2025 operating income has no official split, though cardiometabolic medicines brought in 74.0% of revenue.
Sources and detail on the Eli Lilly page5 · The one thing to watch
In Q3 FY2026 higher volume added 53% to Lilly's revenue while lower prices took off 15%, with price down 7% in the US and 29% outside it.
Sources and detail on the Eli Lilly page
Merck
1 · What it sells
Merck sells prescription medicines, vaccines and animal health products, and Keytruda, a cancer medicine, brought in $31.6 billion of its $65.0 billion of FY2025 sales.
Sources and detail on the Merck page2 · Who pays it
Merck reports no sales by customer or final payer; by location, in FY2025 the US paid 56.2% of sales, Europe, the Middle East and Africa 22.4% and other regions 21.4%.
Sources and detail on the Merck page3 · What it keeps from $100
Of every $100 of FY2025 sales, Merck kept $28.1 as net income after $24.3 of research, and operating income, a Cityfort calculation from the FY2025 10-K, was $32.6.
Sources and detail on the Merck page4 · Where the operating profit comes from
Pharmaceutical segment profit was $45.8 billion in FY2025 and Animal Health's $2.1 billion, before $26.8 billion of costs Merck keeps outside its segments, such as most research and amortization.
Sources and detail on the Merck page5 · The one thing to watch
Keytruda was 49% of Merck's FY2025 sales, and Merck expects a Medicare set price for it from Jan 1, 2029, after its key US patent runs out in 2028.
Sources and detail on the Merck page
Where each $100 went
Each company's own receipt for its latest full fiscal year, with matching lines in the same order where both have them.
Eli Lilly
Where $100 went · FY2025
| Research and development | $20.5 |
|---|---|
| Cost of making medicines | $17.0 |
| Marketing, selling and admin | $17.0 |
| Research bought from others (acquired IPR&D) | $4.5 |
| Special charges and net other costs | $1.6 |
| Income tax | $7.8 |
| Kept as net income | $31.7 |
| Total | $100 |
Cityfort calculation from FY2025 10-K. Of every $100 of revenue in FY2025: each line = line ÷ $65.2 billion × 100. Net other items were a cost, so no other income is added. Rounded lines add to $100.1.
Merck
Where $100 went · FY2025
| Research and development | $24.3 |
|---|---|
| Cost of making products | $25.2 |
| Selling, general and administrative | $16.5 |
| Restructuring and other items | $1.6 |
| Income tax and small items | $4.3 |
| Kept as net income | $28.1 |
| Total | $100 |
Cityfort calculation from the FY2025 10-K. Of every $100 of sales in FY2025: each line = line ÷ $65.0 billion × 100. Other items were a net cost, so no other income is added. Lines are rounded and add to 100.
Line items differ because each company groups its costs its own way in its filings. Only on Eli Lilly's receipt: Cost of making medicines; Marketing, selling and admin; Research bought from others (acquired IPR&D); Special charges and net other costs; Income tax. Only on Merck's receipt: Cost of making products; Selling, general and administrative; Restructuring and other items; Income tax and small items.
Revenue, net income and free cash flow
Up to five fiscal years for each company, drawn on one shared scale per measure. Amounts in US$ as reported (GAAP).
Revenue
Eli Lilly
Merck
See the numbers
Net income
Eli Lilly
Merck
See the numbers
Free cash flow
Eli Lilly
Merck
See the numbers
Growth and net margin, FY2021 to FY2025
Worked out over the years both pages cover, so the two growth figures use the same span. Net margin is net income as a share of revenue, as on each page.
Eli Lilly
- Revenue, per year
- +23.2%
- Net income, per year
- +38.7%
Merck
- Revenue, per year
- +7.5%
- Net income, per year
- +8.8%
Cityfort calculation: compound growth per year from FY2021 to FY2025 (4 years), from each page's yearly numbers, as reported.
Net margin by year
Latest quarter, against the same quarter a year earlier
Each page's latest quarter as reported; the change is a Cityfort calculation.
Eli Lilly
Q3 FY2026, the quarter to Sep 30, 2026, against Q3 FY2025
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $24.4B | $17.6B | +38.6% |
| Net income | $6.5B | $5.6B | +15.6% |
Merck
Q3 FY2026, the quarter to Sep 30, 2026, against Q3 FY2025
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $18.1B | $17.3B | +4.7% |
| Net income | $5.1B | $5.8B | −12.4% |
Sources: Eli Lilly S16, S9, S15, S1, S14, S8, S13, S7, S12, S6 · Merck S18, S9, S16, S17, S1, S15, S8, S14, S7, S12, S6
Who pays each company
Eli Lilly
- Customers in the US · 66.7% of revenue66.7% of FY2025 revenue ($43.5 billion). Most products reach pharmacies, doctors and hospitals through wholesalers. Benefit managers, insurers, employers and government programs negotiate rebates. Shares here are by location, because Lilly does not report revenue by final payer.
- Customers in Europe · 17.7% of revenue17.7% of FY2025 revenue ($11.6 billion).
- Customers in Japan · 3.3% of revenue3.3% of FY2025 revenue ($2.1 billion).
- Customers in China · 3.0% of revenue3.0% of FY2025 revenue ($2.0 billion).
- Customers in the rest of the world · 9.3% of revenue9.3% of FY2025 revenue ($6.1 billion).
Merck
- Customers in the US · 56.2% of revenue56.2% of FY2025 sales ($36.5 billion). Most US sales go through wholesalers. Shares here are by location, because Merck does not report sales by customer or final payer.
- Europe, Middle East and Africa · 22.4% of revenue22.4% of FY2025 sales ($14.6 billion).
- Asia Pacific, including Japan and China · 11.7% of revenue11.7% of FY2025 sales: Japan $2.7 billion, China $1.9 billion and the rest of Asia Pacific $3.0 billion. China fell from $6.8 billion in FY2023.
- Latin America · 5.2% of revenue5.2% of FY2025 sales ($3.4 billion).
- Other · 4.4% of revenue4.4% of FY2025 sales ($2.9 billion), the remainder Merck does not assign to these regions.
Revenue by segment
Eli Lilly
FY2025
| Segment | Revenue | Share |
|---|---|---|
| Cardiometabolic health | $48.2B | 74.0% |
| Oncology | $9.4B | 14.4% |
| Immunology | $5.2B | 8.1% |
| Neuroscience | $1.4B | 2.1% |
| Other | $943M | 1.4% |
Merck
FY2025
| Segment | Revenue | Share |
|---|---|---|
| Pharmaceutical | $58.1B | 89.4% |
| Animal Health | $6.4B | 9.8% |
| Other | $515M | 0.8% |
Where the revenue comes from
Revenue by region, as each company splits it, with the period.
Eli Lilly
FY2025
- United States66.7%
- Europe17.7%
- Rest of world9.3%
- Japan3.3%
- China3.0%
Merck
FY2025
- United States56.2%
- Europe, Middle East and Africa22.4%
- Latin America5.2%
- Asia Pacific (excluding Japan and China)4.6%
- Other4.4%
- Japan4.2%
- China3.0%
Debt and cash
Eli Lilly
- Debt
- $49.5B
- Cash and investments
- $4.9B
On Sep 30, 2026.
At Sep 30, 2026 Lilly's debt exceeded its cash by $44.6 billion, up from $35.2 billion at Dec 31, 2025. That is about 1.2 times EBITDA over the last four quarters.
Merck
- Debt
- $53.8B
- Cash and investments
- $9.6B
On Sep 30, 2026.
At Sep 30, 2026 Merck's debt exceeded its cash by $44.2 billion, up from $34.8 billion at Dec 31, 2025. That is about 2.4 times operating cash flow over the last four quarters (Cityfort calculation from the FY2025 10-K, Q3 FY2025 10-Q and Q3 FY2026 10-Q).
Sources: Eli Lilly S6, S1, S25, S12, S13, S14, S15 · Merck S6, S1, S4, S9, S26, S27
Who owns each company
Eli Lilly
- One class of shares.
- Officers and directors as a group: 0.1% of shares (as of Feb 25, 2026).
- Lilly Endowment Inc.: 9.6% (as of Oct 19, 2026).
- BlackRock, Inc.: 6.8% (as of Jan 29, 2024).
- Vanguard Capital Management: 6.5% (as of May 1, 2026).
- 2 more holders on the Eli Lilly page.
Merck
- One class of shares.
- Officers and directors as a group: 0.2% of shares (as of Feb 28, 2026).
- BlackRock, Inc.: 8.2% (as of Jan 26, 2024).
- Vanguard Capital Management: 7.5% (as of Apr 30, 2026).
- The Vanguard Group: 0.0% (as of Mar 27, 2026).
Sources: Eli Lilly S20, S1, S6, S21, S22, S23 · Merck S22, S6, S23, S24
What protects each business
What each page lists as protecting the business from competitors, each with its written reason. These describe business traits, not the share.
Eli Lilly
- Patents on the main medicines
The US compound patent on tirzepatide has an estimated expiry of 2036, but generic filers notified Lilly in July 2026 that they seek approval before some or all listed patents expire.
- Research spending
Lilly spent $13.3 billion on research and development in FY2025, 20.5% of revenue, plus $2.9 billion on acquired research.
- Manufacturing build-out
Purchases of property and equipment reached $7.8 billion in FY2025, up from $1.3 billion in FY2021. Lilly also depends on China-based suppliers.
- Pricing power
Lower prices cut revenue by 6% in FY2025 and by 14% in the first nine months of 2026, while volume rose.
Merck
- Patents on the main medicines
Keytruda's key US patent runs to 2028 and its EU patent to 2031. Keytruda Qlex's US patent runs to 2043. Januvia and Bridion lost US protection in 2026.
- Research spending
Merck spent $15.8 billion on research and development in FY2025, 24.3% of sales, and about 24,700 employees worked in research.
- Global reach
43.8% of FY2025 sales came from outside the US, across Europe, Asia Pacific and Latin America.
- Pricing power
Medicare set a Januvia price from Jan 1, 2026. Merck expects Keytruda to be selected in 2027 for a set price from Jan 1, 2029. Merck also signed a three-year pricing agreement with the US government in December 2025.
Where growth could come from
Each page's growth drivers. The status compares progress with what the company itself said it would do; it is not a view on the share.
Eli Lilly
- Mounjaro · Working: on track against what the company saidUp 65% in Q3 FY2026
- Zepbound · Working: on track against what the company saidUp 49% in Q3 FY2026
- Foundayo · New: recently announced$184 million in Q3 FY2026
- Outside the US · Mixed: partly on trackVolume +76%, price -29%
- Retatrutide · Early: too early to judgeUS filing planned Q1 2027
- Bought-in programs · New: recently announced$18.2 billion in nine months
Merck
- Keytruda and Keytruda Qlex · Working: on track against what the company said$8.6B in Q3 FY2026, up 6%
- Keytruda Qlex (under the skin) · New: recently announced$830M in Q3 FY2026
- Winrevair · Working: on track against what the company said$694M in Q3 FY2026, up 93%
- Capvaxive · Mixed: partly on track$263M in Q3 FY2026, up 8%
- Gardasil · Mixed: partly on track$2.0B in Q3 FY2026, up 14%
- Ohtuvayre (from Verona Pharma) · New: recently announced$184M in Q3 FY2026
- Bought drug programs · Early: too early to judge$9.2B and $6.8B deals in 2026
Sources: Eli Lilly S12, S6, S13 · Merck S12, S6, S9, S1, S8, S15, S14
Dividends, buybacks, auditor and credit rating
Dividends per share and buybacks for up to five years, the independent auditor and the latest credit rating, as each page records them.
Eli Lilly
- Dividends per shareFY2021: $3.40 (55.3% of profit) · FY2022: $3.92 (56.6% of profit) · FY2023: $4.52 (77.7% of profit) · FY2024: $5.20 (44.2% of profit) · FY2025: $6.00 (26.1% of profit)
- Buybacks
- Dec 31, 2025: Bought $4.1 billion of its own shares during FY2025, up from $2.5 billion in FY2024. ($4.1B)
- Sep 30, 2026: Bought $4.3 billion of its own shares in the first nine months of 2026, leaving $6.6 billion on its $15.0 billion program. ($4.3B)
- AuditorErnst & Young LLP, since 1940
- Credit ratingNot checked for this page.
Merck
- Dividends per shareFY2021: $2.64 (50.7% of profit) · FY2022: $2.80 (48.3% of profit) · FY2023: $2.96 · FY2024: $3.12 (45.8% of profit) · FY2025: $3.28 (44.8% of profit)
- Buybacks
- Dec 31, 2025: Bought about 59 million of its own shares for $5.1 billion in 2025. This was under a $10 billion authorization from January 2025 with no time limit, and $7.3 billion remained at Dec 31, 2025. ($5.1B)
- Sep 30, 2026: Bought $2.3 billion of its own shares in the first nine months of 2026. ($2.3B)
- AuditorPricewaterhouseCoopers LLP, since 2002
- Credit ratingMoody's and S&P (expected ratings of the May 2026 notes, per Merck's pricing term sheet): Aa3 and A+, outlook Stable (May 18, 2026)
Sources: Eli Lilly S4, S3, S2, S1, S6 · Merck S3, S1, S6, S26
Risks only one page tracks
Risks whose type the other company's page does not list. Both pages track risks of these types: customer or supplier concentration, pricing, competition, execution, debt, legal cases. Every risk is on each company's page.
Eli Lilly
Every risk type on the Eli Lilly page also appears on the other page.
Merck
- Gardasil sales in China and the US (demand)China sales fell from $6.8 billion in FY2023 to $1.9 billion in FY2025 after Gardasil shipments there were suspended. Merck expects a 2026 US public-sector purchasing benefit to largely unwind in 2027.
Key facts
- How does Eli Lilly make money compared with Merck?
- Eli Lilly's revenue by segment in FY2025: Cardiometabolic health 74.0%, Oncology 14.4%, Immunology 8.1%, Neuroscience 2.1%, Other 1.4%. Merck's revenue by segment in FY2025: Pharmaceutical 89.4%, Animal Health 9.8%, Other 0.8%.
- Which is bigger by revenue, Eli Lilly or Merck?
- Eli Lilly reported $65.2B of revenue in FY2025, and Merck reported $65.0B in FY2025.
- How much net income did Eli Lilly and Merck report?
- Eli Lilly reported net income of $20.6B in FY2025, and Merck reported $18.3B in FY2025.
- How much of every $100 did Eli Lilly and Merck keep as net income?
- Eli Lilly kept $31.7 of every $100 that came in during FY2025, and Merck kept $28.1 in FY2025 (Cityfort calculation from each company's annual report).
- How much debt and cash do Eli Lilly and Merck have?
- Eli Lilly had $49.5B of debt and $4.9B of cash and investments on Sep 30, 2026. Merck had $53.8B of debt and $9.6B of cash and investments on Sep 30, 2026.
- When do Eli Lilly's and Merck's fiscal years end?
- Eli Lilly: December 31. Merck: December 31.
Sources: Eli Lilly S3, S1, S19, S15, S6, S25, S12, S13, S14 · Merck S3, S1, S6, S4, S9, S26, S27
Built from each company's page. Eli Lilly updated Nov 1, 2026; Merck updated Nov 6, 2026.
Sources
Eli Lilly
- S1Form 10-K for fiscal year 2025 (ended Dec 31, 2025), Eli Lilly and Company (SEC EDGAR), Feb 12, 2026
- S2Form 10-K for fiscal year 2024, Eli Lilly and Company (SEC EDGAR), Feb 19, 2025
- S3Form 10-K for fiscal year 2023, Eli Lilly and Company (SEC EDGAR), Feb 21, 2024
- S4Form 10-K for fiscal year 2022, Eli Lilly and Company (SEC EDGAR), Feb 22, 2023
- S6Form 10-Q for Q3 FY2026 (ended Sep 30, 2026), Eli Lilly and Company (SEC EDGAR), Oct 29, 2026
- S7Form 10-Q for Q2 FY2026 (ended Jun 30, 2026), Eli Lilly and Company (SEC EDGAR), Aug 5, 2026
- S8Form 10-Q for Q1 FY2026 (ended Mar 31, 2026), Eli Lilly and Company (SEC EDGAR), Apr 30, 2026
- S9Form 10-Q for Q3 FY2025 (ended Sep 30, 2025), Eli Lilly and Company (SEC EDGAR), Oct 30, 2025
- S12Earnings release, Q3 FY2026 (8-K Ex. 99.1), Eli Lilly and Company (SEC EDGAR), Oct 29, 2026
- S13Earnings release, Q2 FY2026 (8-K Ex. 99.1), Eli Lilly and Company (SEC EDGAR), Aug 5, 2026
- S14Earnings release, Q1 FY2026 (8-K Ex. 99.1), Eli Lilly and Company (SEC EDGAR), Apr 30, 2026
- S15Earnings release, Q4 FY2025 (8-K Ex. 99.1), Eli Lilly and Company (SEC EDGAR), Feb 4, 2026
- S16Earnings release, Q3 FY2025 (8-K Ex. 99.1), Eli Lilly and Company (SEC EDGAR), Oct 30, 2025
- S19Earnings release, Q4 FY2024 (8-K Ex. 99.1), Eli Lilly and Company (SEC EDGAR), Feb 6, 2025
- S20Proxy statement (DEF 14A) for the 2026 annual meeting, Eli Lilly and Company (SEC EDGAR), Mar 20, 2026
- S21Schedule 13G/A, Lilly Endowment Inc., event Sep 30, 2026, Lilly Endowment Inc. (SEC EDGAR), Oct 19, 2026
- S22Schedule 13G, Vanguard Capital Management, event Mar 31, 2026, Vanguard Capital Management (SEC EDGAR), May 1, 2026
- S23Schedule 13G/A, The Vanguard Group, event Mar 13, 2026, The Vanguard Group (SEC EDGAR), Mar 26, 2026
- S25Form 8-K Item 8.01, senior notes offering completed May 20, 2026, Eli Lilly and Company (SEC EDGAR), May 20, 2026
Merck
- S1Form 10-K for fiscal year 2025 (ended Dec 31, 2025), Merck & Co., Inc. (SEC EDGAR), Feb 24, 2026
- S3Form 10-K for fiscal year 2023, Merck & Co., Inc. (SEC EDGAR), Feb 26, 2024
- S4Form 10-K for fiscal year 2022, Merck & Co., Inc. (SEC EDGAR), Feb 24, 2023
- S6Form 10-Q for Q3 FY2026 (ended Sep 30, 2026), Merck & Co., Inc. (SEC EDGAR), Nov 4, 2026
- S7Form 10-Q for Q2 FY2026 (ended Jun 30, 2026), Merck & Co., Inc. (SEC EDGAR), Aug 7, 2026
- S8Form 10-Q for Q1 FY2026 (ended Mar 31, 2026), Merck & Co., Inc. (SEC EDGAR), May 4, 2026
- S9Form 10-Q for Q3 FY2025 (ended Sep 30, 2025), Merck & Co., Inc. (SEC EDGAR), Nov 5, 2025
- S12Earnings release, Q3 FY2026 (8-K Ex. 99.1), Merck & Co., Inc. (SEC EDGAR), Oct 29, 2026
- S14Earnings release, Q2 FY2026 (8-K Ex. 99.1), Merck & Co., Inc. (SEC EDGAR), Aug 4, 2026
- S15Earnings release, Q1 FY2026 (8-K Ex. 99.1), Merck & Co., Inc. (SEC EDGAR), Apr 30, 2026
- S16Earnings release, Q4 FY2025 and full year 2025 (8-K Ex. 99.1), Merck & Co., Inc. (SEC EDGAR), Feb 3, 2026
- S17Financial tables, Q4 FY2025 (8-K Ex. 99.2), Merck & Co., Inc. (SEC EDGAR), Feb 3, 2026
- S18Earnings release, Q3 FY2025 (8-K Ex. 99.1), Merck & Co., Inc. (SEC EDGAR), Oct 30, 2025
- S22Proxy statement (DEF 14A) for the 2026 annual meeting, Merck & Co., Inc. (SEC EDGAR), Apr 8, 2026
- S23Schedule 13G, Vanguard Capital Management, event Mar 31, 2026, Vanguard Capital Management (SEC EDGAR), Apr 30, 2026
- S24Schedule 13G/A, The Vanguard Group, event Mar 13, 2026, The Vanguard Group (SEC EDGAR), Mar 27, 2026
- S26Pricing term sheet (FWP) for $6.0 billion senior notes, May 18, 2026, Merck & Co., Inc. (SEC EDGAR), May 19, 2026
- S27Form 8-K Item 8.01, senior notes offering closed May 22, 2026, Merck & Co., Inc. (SEC EDGAR), May 22, 2026
Disclaimer
For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a registered investment adviser or other qualified professional.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Cityfort is not paid by any company it covers. Content is not an offer or solicitation to buy or sell any security, including in any initial public offering.
Read the positions policyRead the full disclaimerHide the full disclaimer
Cityfort publishes general educational content that explains how listed companies work. Cityfort is not registered with the US Securities and Exchange Commission or any state securities regulator as an investment adviser, and is not a broker-dealer or a member of FINRA. Cityfort does not provide investment, tax or legal advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security. Nothing on the site is tailored to any person's circumstances.
All information is taken from publicly available sources, mainly company filings with the SEC, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management, including forward-looking statements and guidance, are reported as the company's statements, with their date and source; they are not our forecasts. Adjusted (non-GAAP) figures are the company's own measures and are shown next to the official (GAAP) figures.